Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Codiak Biosciences Inc (CDAK)
Codiak Biosciences Inc (CDAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,099
  • Shares Outstanding, K 36,830
  • Annual Sales, $ 22,940 K
  • Annual Income, $ -37,160 K
  • 60-Month Beta 3.71
  • Price/Sales 0.04
  • Price/Cash Flow N/A
  • Price/Book 0.05
Trade CDAK with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.43
  • Most Recent Earnings $-0.77 on 11/03/22
  • Latest Earnings Date 05/04/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 352.40%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +277,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0532 +7.14%
on 04/04/23
0.6200 -90.81%
on 03/17/23
-0.4990 (-89.75%)
since 03/03/23
3-Month
0.0532 +7.14%
on 04/04/23
0.9378 -93.92%
on 02/03/23
-0.4580 (-88.93%)
since 01/04/23
52-Week
0.0532 +7.14%
on 04/04/23
6.9800 -99.18%
on 04/05/22
-6.9030 (-99.18%)
since 04/04/22

Most Recent Stories

More News
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

CDAK : 0.0570 (-55.98%)
BLUE : 1.5650 (+12.59%)
Sanofi (SNY) Q3 Earnings Beat, Dupixent, Flu Jabs Push Sales

Sanofi (SNY) beats third-quarter estimates for earnings and sales. Dupixent and flu vaccines drive sales growth. The company raises its earnings growth guidance for 2022.

REGN : 982.82 (+1.73%)
SNY : 47.29 (-1.17%)
CSTL : 19.94 (+10.41%)
CDAK : 0.0570 (-55.98%)
Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales Guidance

Vertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue guidance for 2022. The stock rises in the after-market trading.

VRTX : 432.76 (+2.86%)
CRSP : 83.75 (-0.56%)
MORF : 39.53 (+6.98%)
CDAK : 0.0570 (-55.98%)
Amarin (AMRN) Q3 Earnings Beat, Sales Hurt by Vascepa Generics

Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and the restructuring initiatives in the third quarter. The stock witnesses a decline on Oct 27.

AMRN : 1.0600 (-0.93%)
PBYI : 5.89 (-5.31%)
ETON : 4.46 (+0.22%)
CDAK : 0.0570 (-55.98%)
BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View

BioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark.

SNY : 47.29 (-1.17%)
BMRN : 87.14 (+1.00%)
MORF : 39.53 (+6.98%)
CDAK : 0.0570 (-55.98%)
Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook

Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance.

BIIB : 220.95 (+1.82%)
RHHBY : 33.0800 (+1.07%)
MORF : 39.53 (+6.98%)
CDAK : 0.0570 (-55.98%)
All You Need to Know About Codiak BioSciences, Inc. (CDAK) Rating Upgrade to Strong Buy

Codiak BioSciences, Inc. (CDAK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

CDAK : 0.0570 (-55.98%)
J&J (JNJ) Beats on Q3 Earnings, Cuts 2022 Sales View on Fx Woes

J&J (JNJ) beats estimates for third-quarter earnings as well as sales. It lowers the full-year sales guidance. Stock up

JNJ : 162.12 (+0.46%)
KMDA : 6.37 (+1.11%)
CSTL : 19.94 (+10.41%)
CDAK : 0.0570 (-55.98%)
United Therapeutics (UTHR) Initiates Tyvaso Study in IPF

United Therapeutics (UTHR) initiates a second phase III study evaluating its Tyvaso inhalation solution. The study will be conducted in sites outside the United States and Canada.

UTHR : 231.92 (+2.78%)
CPRX : 17.01 (+6.11%)
AERI : 15.25 (+0.07%)
CDAK : 0.0570 (-55.98%)
Vertex Pharmaceuticals' (VRTX) New AAT Corrector Enters Clinic

The FDA clears Vertex's (VRTX) Investigational New Drug application for VX-634, a small molecule AAT corrector, thereby allowing the company to initiate a first-in-human clinical study in healthy volunteers....

VRTX : 432.76 (+2.86%)
KMDA : 6.37 (+1.11%)
CSTL : 19.94 (+10.41%)
CDAK : 0.0570 (-55.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Codiak BioSciences Inc. is a clinical-stage biopharmaceutical company. It is focused on development of exosome-based therapeutics for spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. Codiak BioSciences Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 0.1504
2nd Resistance Point 0.1302
1st Resistance Point 0.0936
Last Price 0.0570
1st Support Level 0.0368
2nd Support Level 0.0166
3rd Support Level N/A

See More

52-Week High 6.9800
Fibonacci 61.8% 4.3340
Fibonacci 50% 3.5166
Fibonacci 38.2% 2.6992
Last Price 0.0570
52-Week Low 0.0532

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar